Biogen

Biogen Appoints Monish Patolawala to its Board of Directors

Retrieved on: 
Monday, November 6, 2023
GE HealthCare, Biogen, Commerce, BIIB, General Electric Company, Information technology, Cost, KPMG, Audit committee, Management

CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company (“3M”), to the Company’s Board of Directors (the “Board”), effective January 1, 2024.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company (“3M”), to the Company’s Board of Directors (the “Board”), effective January 1, 2024.
  • “We are pleased to welcome Monish to the Board as the Company is advancing on its next chapter,” said Caroline Dorsa, Chair of the Biogen Board of Directors.
  • “Monish brings new perspective and expertise to our Board during an important time in our ongoing transformation at Biogen,” said Chris Viehbacher, Biogen President and CEO.
  • Mr. Patolawala has experience leading complex businesses and financial operations through changing business cycles and interest rate environments.

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

Retrieved on: 
Friday, November 3, 2023
FDA, Research, Regenerative Medicine Advanced Therapy, Food, Spinal muscular atrophy, Biogen, SCD, Life, Public expenditure, TDT, Cas9, Sickle cell disease, Regulation of tobacco by the U.S. Food and Drug Administration, Poster, Society, ASH, Commercialization, HSC, File, Fetal hemoglobin, Collaboration, Lead, Beta thalassemia, Anemia, Multiple sclerosis, Bone marrow, Therapy, Patient, BLA, MS, Pharmaceutical industry, Cryptocurrency, Edith A. Perez, Editas Medicine, EU

CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and provided business updates.

Key Points: 
  • CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today reported financial results for the third quarter 2023 and provided business updates.
  • Cash, cash equivalents, and marketable securities as of September 30, 2023, were $446.4 million compared to $480.0 million as of June 30, 2023.
  • The increase is primarily related to an upfront payment for the non-exclusive Cas9 license to Vor Bio in the third quarter of 2023.
  • Editas Medicine plans to participate in the following scientific and medical conference:
    Editas Medicine plans to participate in the following investor events:

C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, November 1, 2023
Neoplasm, Controlled Impact Demonstration, Research, NSCLC, Public expenditure, National Medical Products Administration, Dexamethasone, Disease, CRC, Annual general meeting, Security (finance), Melanoma, BRAF, Wind, Caregiver, Roche, NHL, Safety, Therapy, Patient, Administration, BRAF V600, Research and development, Plasma, CCCC, Xerostomia, G&A, Conference, CTA, Synovial sarcoma, TPD, Clinical trial, ODI, Anemia, BRD9, Finance, Fatigue, Half-life, NMPA, Aes, Strategic planning, Colorectal cancer, R, High-level radioactive waste management, RECIST, Lung cancer, Combination therapy, Neutropenia, Pharmaceutical industry, Cryptocurrency, Fine chemical, Vaccine, Video game, Dysgeusia, Biogen

WATERTOWN, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today reported financial results for the third quarter ended September 30, 2023, as well as recent business highlights.

Key Points: 
  • Revenue: Total revenue for the third quarter of 2023 was $11.1 million, compared to $6.8 million for the third quarter of 2022.
  • Research and Development (R&D) Expense: R&D expense for the third quarter of 2023 was $28.3 million, compared to $29.7 million for the third quarter of 2022.
  • Net Loss and Net Loss per Share: Net loss for the third quarter of 2023 was $27.0 million, compared to $32.0 million for the third quarter of 2022.
  • Net loss per share for the third quarter of 2023 was $0.55 compared to $0.65 for the third quarter of 2022.

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

Retrieved on: 
Wednesday, November 1, 2023
Bluebird bio, IND, Ridgeback Biotherapeutics, Johns Hopkins University, Biogen, Therapy, University, Biotechnology, Head, MBA, Hotspot, Drug development, Sensei, Swedish Orphan Biovitrum, Neurology, Cancer, Patient, MS, Pharmaceutical industry

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.

Key Points: 
  • BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer.
  • Ms. Krebs joins Sensei from SNIPR Biome, a clinical-stage biotechnology company where, as Chief Business Officer, she was responsible for defining the company’s growth and partnering activities, including value creation through collaborations with large pharmaceutical and biotech partners.
  • Ms. Krebs holds an MS in biotechnology from Johns Hopkins University and an MBA from the University of Rochester.
  • “We’re delighted to welcome Stephanie to our leadership team at such an exciting moment for Sensei, as we advance the ongoing Phase 1/2 clinical trial of our lead candidate SNS-101 and prepare to move an additional candidate toward IND-enabling studies,” said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics.

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, November 1, 2023
Health, General Health, Research, Pharmaceutical, Science, Biotechnology, Regenerative Medicine Advanced Therapy, Ethics, Therapy, Pfizer, Gene, Partnership, Head, Exposition, European Society of Gene and Cell Therapy, ALTA, AAV, Haemophilia, Hope, 65th Street Yard, Workforce, ERT, DSM-IV codes, Cell, CAR, U.S. FDA, Safety, Investment, Patient, Central nervous system, Nav1.7, MAA, 22q13 deletion syndrome, Conference, Enzyme replacement therapy, Hematology, Quality of life, Mace Head Atmospheric Research Station, Novartis, Brain, European Society for Primary Immunodeficiencies, Haemophilia A, Spectrum, FDA, IND, Fabry disease, Prion, Society, Senior, SCN2A, ESGCT, STAAR, Intellectual disability, Sclerosis, BLA, Pharmaceutical industry, Management, Vaccine, Biogen, Neuroscience, Fabry, Sangamo Therapeutics

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and reported third quarter 2023 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and reported third quarter 2023 financial results.
  • As a result of this restructuring, Sangamo is reducing its US workforce by approximately 40%, or approximately 162 roles.
  • Sangamo expects to incur approximately $8 million-$10 million in one-time restructuring costs in the fourth quarter of 2023.
  • Revenues for the third quarter ended September 30, 2023 were $9.4 million, compared to $26.5 million for the same period in 2022.

LCDA's 8th Annual Board Leaders Convening Hosted by Toyota: Heading to Texas

Retrieved on: 
Thursday, November 2, 2023
Bank, Biogen, Federal Home Loan Banks, Corporation, Organization, Celebrity board director, Bank of America, Convening authority (court-martial), Annual, Ulta Beauty, KPMG, Lone Star, General Mills, Management

WASHINGTON, Nov. 2, 2023 /PRNewswire/ -- The Latino Corporate Directors Association (LCDA) brings its flagship event, LCDA's 8th Annual Board Leaders Convening, to the Lone Star State for the very first time. The Convening is the largest gathering of Latino business leaders at the pinnacle of corporate leadership and governance, and this year's event promises to be bigger and better than ever.

Key Points: 
  • LCDA's Annual Meeting Focused on Trending Governance Topics, featuring CEOs, Board Directors, and C-Level Executives Across Industries
    WASHINGTON, Nov. 2, 2023 /PRNewswire/ -- The Latino Corporate Directors Association (LCDA) brings its flagship event, LCDA's 8th Annual Board Leaders Convening , to the Lone Star State for the very first time.
  • The Convening is the largest gathering of Latino business leaders at the pinnacle of corporate leadership and governance, and this year's event promises to be bigger and better than ever.
  • LCDA Chair Elizabeth Oliver-Farrow expressed, "Bringing LCDA's 8th Annual Board Leaders Convening to Texas is a momentous occasion.
  • This Convening underscores our commitment to promoting equity and inclusion at the highest levels of corporate leadership."

LEQEMBI (lecanemab-Irmb) Named One of Time's Best Inventions of 2023

Retrieved on: 
Wednesday, October 25, 2023
Lecanemab, Alzheimer's disease, BEST, AD, Biogen, Health care, TIME, Pathology, Co-promotion, HIV disease progression rates, Dementia, Eisai, Disease, AI, Patient, Pharmaceutical industry

TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.

Key Points: 
  • TOKYO, Oct 25, 2023 - (JCN Newswire) - Eisai Co. Ltd. announced today that TIME has selected Alzheimer's disease (AD) treatment LEQEMBI (lecanemab-irmb) as one of THE BEST INVENTIONS of 2023 in the Medical Care category.
  • TIME's annual list of THE BEST INVENTIONS features "200 extraordinary innovations changing lives."
  • TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact.
  • We will deliver LEQEMBI to the people with early AD who need it and their families, and aim to continue creating impact on global issues surrounding dementia.

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

Retrieved on: 
Wednesday, October 25, 2023
Headache, Neuron, Biogen, Biomarker, ASO, CSF, International Conference on Emerging Infectious Diseases, Pathology, Conference, MAPT, BIIB, PET, LTE, Disease, Cancer, Messenger, MMSE, FAQ, Safety, Ionis, Pain, Patient, Back pain, Cognition, Pharmaceutical industry, Dietary supplement, Medical imaging

First study of a tau targeting drug that shows reduction of aggregated tau pathology and favorable trends on clinical outcomes.

Key Points: 
  • First study of a tau targeting drug that shows reduction of aggregated tau pathology and favorable trends on clinical outcomes.
  • CAMBRIDGE, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in mild Alzheimer’s disease (AD).
  • The late-breaking results were presented at the 2023 Clinical Trials on Alzheimer’s Disease (CTAD) meeting held in Boston, MA from October 24-27.
  • The favorable trends suggest a potential link between a reduction in tau PET pathology and clinical outcomes.

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

Retrieved on: 
Thursday, October 19, 2023
Week, Alzheimer's disease, Amyloid, Patient, AD, Biogen, Clarity, MAPT, HIV disease progression rates, Clinical trial, BIIB, PET, LTE, Caregiver, CLARITY, Biomarker, Safety, Pharmaceutical industry, Medical imaging

CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer’s disease portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) meeting taking place October 24-27 in Boston, Mass.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) will present new data from its Alzheimer’s disease portfolio at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD) meeting taking place October 24-27 in Boston, Mass.
  • The presentations will advance the understanding of Alzheimer’s disease with data on different treatment approaches, predictive analysis of disease progression, and clinical meaningfulness of amyloid removal for patients and their caregivers.
  • The presentation will include the latest data from the CLARITY AD optional tau PET longitudinal sub-study.
  • Oral presentation: Precision medicine analysis of heterogeneity in individual-level treatment response to beta-amyloid removal in early Alzheimer’s disease: Thursday, October 26, 4:35 p.m.

Mediar Therapeutics Announces Clinical Candidates for Lead Fibrosis Programs, Strategic Collaborations and Key Leadership Addition

Retrieved on: 
Wednesday, October 25, 2023
Takeda Pharmaceutical Company, Gastroenterology, Clinical Science (journal), Faculty, Research, CGMP, IND, Biogen, Hepatitis C, CMC, Conditional sentence, Liver, Fibrosis, Idiopathic pulmonary fibrosis, Primary sclerosing cholangitis, IPF, Gilead Sciences, McGill University, PSC, Death, Lung, NASH, KOL, Antibody, Partnership, Internal medicine, Chief medical informatics officer, Therapy, Patient, Fatty liver disease, WuXi Biologics, Pharmaceutical industry, Vaccine, Linking and intrusive R

CAMBRIDGE, Mass., Oct. 25, 2023 /PRNewswire/ -- Mediar Therapeutics Inc., a biotechnology company advancing a portfolio of first-in-class therapies that halt fibrosis progression, today announced several milestones that support clinical advancement of its portfolio of novel antibodies: the nomination of two clinical candidates, key strategic collaborations with Pfizer Ignite and WuXi Biologics, and the appointment of Jeffrey D. Bornstein, M.D., as Chief Medical Officer.

Key Points: 
  • Mediar's first candidate, MTX-463, is a first-in-class monoclonal antibody designed to neutralize the WISP-1 signaling that is elevated in and contributes to fibrosis progression.
  • Its second candidate, MTX-474, is a first-in-class monoclonal antibody designed to neutralize the EphrinB2 signaling that causes fibrosis advancement and may play a role in defining the fibrotic niche.
  • Mediar plans to advance both MTX-463 and MTX-474 into Phase 1 clinical development in 2024.
  • In addition, he directed development programs, including those focused on fibrosis, at Biogen, Gilead Sciences, Elan Pharmaceuticals and other early-stage biotechnology companies.